Compounds > 6,7-dichloroquinoline-5,8-dione
Page last updated: 2024-11-07

6,7-dichloroquinoline-5,8-dione

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

6,7-dichloro-5,8-quinolinedione: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID96582
CHEMBL ID132160
SCHEMBL ID1612462
MeSH IDM0163127

Synonyms (32)

Synonym
STK720283
NCI60_041779
6,7-dichloro-5,8-quinolinequinone
nsc-81047
6541-19-1
5, 6,7-dichloro-
6,8-quinolinedione
6,8-quinolinequinone
nsc81047
da 3002
5,8-quinolinedione, 6,7-dichloro-
6,7-dichloroquinoline-5,8-dione
inchi=1/c9h3cl2no2/c10-5-6(11)9(14)7-4(8(5)13)2-1-3-12-7/h1-3
6,7-dichloro-quinoline-5,8-dione
CHEMBL132160 ,
AKOS000714983
bdbm50106501
6,7-dqdo
nsc 81047
SCHEMBL1612462
TUWOPVCIIBKUQS-UHFFFAOYSA-N
6,7-dichloro-5,8-quinolinedione
DTXSID50215723
c9h3cl2no2
mfcd00512152
AS-60515
6,7-dichloro-5,8-dihydroquinoline-5,8-dione
5,8-quinolinedione,6,7-dichloro-
W10458
SB71586
CS-0155573
SY124961
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (5)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Genome polyproteinCoxsackievirus B3 (strain Nancy)IC50 (µMol)0.63000.63001.37672.4000AID1393009
Tyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)IC50 (µMol)10.00000.00053.49849.7600AID157201
M-phase inducer phosphatase 2Homo sapiens (human)IC50 (µMol)4.60000.10002.31039.5100AID51883
Dual specificity protein phosphatase 3Homo sapiens (human)IC50 (µMol)10.00004.00005.97508.5000AID217196
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Protein S100-A4Homo sapiens (human)EC50 (µMol)14.00003.80005.70007.6000AID1618872
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (52)

Processvia Protein(s)Taxonomy
positive regulation of JUN kinase activityTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
protein dephosphorylationTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
insulin receptor signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
regulation of signal transductionTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of signal transductionTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
actin cytoskeleton organizationTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
regulation of endocytosisTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of vascular endothelial growth factor receptor signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
endoplasmic reticulum unfolded protein responseTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
regulation of intracellular protein transportTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
cellular response to unfolded proteinTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
peptidyl-tyrosine dephosphorylationTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
platelet-derived growth factor receptor-beta signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
IRE1-mediated unfolded protein responseTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
insulin receptor recyclingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of MAP kinase activityTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of insulin receptor signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
regulation of type I interferon-mediated signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
growth hormone receptor signaling pathway via JAK-STATTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
positive regulation of protein tyrosine kinase activityTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of ERK1 and ERK2 cascadeTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
regulation of hepatocyte growth factor receptor signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of endoplasmic reticulum stress-induced intrinsic apoptotic signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
positive regulation of IRE1-mediated unfolded protein responseTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of PERK-mediated unfolded protein responseTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
peptidyl-tyrosine dephosphorylation involved in inactivation of protein kinase activityTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
positive regulation of receptor catabolic processTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
epithelial to mesenchymal transitionProtein S100-A4Homo sapiens (human)
positive regulation of canonical NF-kappaB signal transductionProtein S100-A4Homo sapiens (human)
positive chemotaxisProtein S100-A4Homo sapiens (human)
G2/M transition of mitotic cell cycleM-phase inducer phosphatase 2Homo sapiens (human)
mitotic cell cycleM-phase inducer phosphatase 2Homo sapiens (human)
oocyte maturationM-phase inducer phosphatase 2Homo sapiens (human)
protein phosphorylationM-phase inducer phosphatase 2Homo sapiens (human)
female meiosis IM-phase inducer phosphatase 2Homo sapiens (human)
positive regulation of cell population proliferationM-phase inducer phosphatase 2Homo sapiens (human)
positive regulation of G2/M transition of mitotic cell cycleM-phase inducer phosphatase 2Homo sapiens (human)
positive regulation of cytokinesisM-phase inducer phosphatase 2Homo sapiens (human)
positive regulation of mitotic cell cycleM-phase inducer phosphatase 2Homo sapiens (human)
cell divisionM-phase inducer phosphatase 2Homo sapiens (human)
positive regulation of G2/MI transition of meiotic cell cycleM-phase inducer phosphatase 2Homo sapiens (human)
dephosphorylationDual specificity protein phosphatase 3Homo sapiens (human)
negative regulation of cell migrationDual specificity protein phosphatase 3Homo sapiens (human)
peptidyl-tyrosine dephosphorylationDual specificity protein phosphatase 3Homo sapiens (human)
negative regulation of epidermal growth factor receptor signaling pathwayDual specificity protein phosphatase 3Homo sapiens (human)
negative regulation of MAPK cascadeDual specificity protein phosphatase 3Homo sapiens (human)
positive regulation of mitotic cell cycleDual specificity protein phosphatase 3Homo sapiens (human)
negative regulation of JNK cascadeDual specificity protein phosphatase 3Homo sapiens (human)
negative regulation of T cell receptor signaling pathwayDual specificity protein phosphatase 3Homo sapiens (human)
negative regulation of T cell activationDual specificity protein phosphatase 3Homo sapiens (human)
negative regulation of chemotaxisDual specificity protein phosphatase 3Homo sapiens (human)
regulation of focal adhesion assemblyDual specificity protein phosphatase 3Homo sapiens (human)
negative regulation of ERK1 and ERK2 cascadeDual specificity protein phosphatase 3Homo sapiens (human)
cellular response to epidermal growth factor stimulusDual specificity protein phosphatase 3Homo sapiens (human)
positive regulation of focal adhesion disassemblyDual specificity protein phosphatase 3Homo sapiens (human)
peptidyl-tyrosine dephosphorylation involved in inactivation of protein kinase activityDual specificity protein phosphatase 3Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (26)

Processvia Protein(s)Taxonomy
RNA bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
protein tyrosine phosphatase activityTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
insulin receptor bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
protein bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
zinc ion bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
enzyme bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
protein kinase bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
receptor tyrosine kinase bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
cadherin bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
ephrin receptor bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
protein phosphatase 2A bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
non-membrane spanning protein tyrosine phosphatase activityTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
RNA bindingProtein S100-A4Homo sapiens (human)
actin bindingProtein S100-A4Homo sapiens (human)
protein bindingProtein S100-A4Homo sapiens (human)
chemoattractant activityProtein S100-A4Homo sapiens (human)
identical protein bindingProtein S100-A4Homo sapiens (human)
transition metal ion bindingProtein S100-A4Homo sapiens (human)
RAGE receptor bindingProtein S100-A4Homo sapiens (human)
calcium-dependent protein bindingProtein S100-A4Homo sapiens (human)
calcium ion bindingProtein S100-A4Homo sapiens (human)
phosphoprotein phosphatase activityM-phase inducer phosphatase 2Homo sapiens (human)
protein tyrosine phosphatase activityM-phase inducer phosphatase 2Homo sapiens (human)
protein bindingM-phase inducer phosphatase 2Homo sapiens (human)
protein kinase bindingM-phase inducer phosphatase 2Homo sapiens (human)
protein tyrosine phosphatase activityDual specificity protein phosphatase 3Homo sapiens (human)
protein bindingDual specificity protein phosphatase 3Homo sapiens (human)
cytoskeletal protein bindingDual specificity protein phosphatase 3Homo sapiens (human)
protein tyrosine/serine/threonine phosphatase activityDual specificity protein phosphatase 3Homo sapiens (human)
phosphatase activityDual specificity protein phosphatase 3Homo sapiens (human)
myosin phosphatase activityDual specificity protein phosphatase 3Homo sapiens (human)
protein kinase bindingDual specificity protein phosphatase 3Homo sapiens (human)
receptor tyrosine kinase bindingDual specificity protein phosphatase 3Homo sapiens (human)
MAP kinase phosphatase activityDual specificity protein phosphatase 3Homo sapiens (human)
protein tyrosine kinase bindingDual specificity protein phosphatase 3Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (21)

Processvia Protein(s)Taxonomy
plasma membraneTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
cytoplasmTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
mitochondrial matrixTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
early endosomeTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
endoplasmic reticulumTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
cytosolTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
mitochondrial cristaTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
endosome lumenTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
sorting endosomeTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
cytoplasmic side of endoplasmic reticulum membraneTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
protein-containing complexTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
endoplasmic reticulumTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
cytoplasmTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
early endosomeTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
extracellular spaceProtein S100-A4Homo sapiens (human)
extracellular regionProtein S100-A4Homo sapiens (human)
extracellular spaceProtein S100-A4Homo sapiens (human)
nucleusProtein S100-A4Homo sapiens (human)
nucleoplasmProtein S100-A4Homo sapiens (human)
cytosolProtein S100-A4Homo sapiens (human)
perinuclear region of cytoplasmProtein S100-A4Homo sapiens (human)
collagen-containing extracellular matrixProtein S100-A4Homo sapiens (human)
extracellular exosomeProtein S100-A4Homo sapiens (human)
perinuclear region of cytoplasmProtein S100-A4Homo sapiens (human)
nucleusProtein S100-A4Homo sapiens (human)
spindle poleM-phase inducer phosphatase 2Homo sapiens (human)
nucleoplasmM-phase inducer phosphatase 2Homo sapiens (human)
centrosomeM-phase inducer phosphatase 2Homo sapiens (human)
cytosolM-phase inducer phosphatase 2Homo sapiens (human)
nucleusM-phase inducer phosphatase 2Homo sapiens (human)
cytoplasmM-phase inducer phosphatase 2Homo sapiens (human)
immunological synapseDual specificity protein phosphatase 3Homo sapiens (human)
nucleusDual specificity protein phosphatase 3Homo sapiens (human)
nucleoplasmDual specificity protein phosphatase 3Homo sapiens (human)
cytosolDual specificity protein phosphatase 3Homo sapiens (human)
cytosolDual specificity protein phosphatase 3Homo sapiens (human)
cytoplasmDual specificity protein phosphatase 3Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (52)

Assay IDTitleYearJournalArticle
AID480961Antiproliferative activity against human HL60 cells after 48 hrs by MTT assay2010Bioorganic & medicinal chemistry, May-01, Volume: 18, Issue:9
The anti-cancer, anti-inflammatory and tuberculostatic activities of a series of 6,7-substituted-5,8-quinolinequinones.
AID1631061Binding affinity to HIV1 MA expressed in bacterial expression system assessed as inhibition of protein binding to Sel15 RNA at 50 uM preincubated for 30 mins followed by Sel15 RNA addition measured after 30 mins in presence of TCEP by electrophoretic mobi2016Bioorganic & medicinal chemistry, 11-01, Volume: 24, Issue:21
Analysis of quinolinequinone reactivity, cytotoxicity, and anti-HIV-1 properties.
AID1434240Selectivity index, ratio of IC50 for HFF1 to IC50 for human SNB19 cells harboring undetectable levels of NQO12017European journal of medicinal chemistry, Jan-27, Volume: 126Alkynyloxy derivatives of 5,8-quinolinedione: Synthesis, in vitro cytotoxicity studies and computational molecular modeling with NAD(P)H:Quinone oxidoreductase 1.
AID1631046Inhibition of HIV1 NL4-3 PrGag infected in CEM T cells at 1 uM after 7 days by immunoblot analysis relative to control2016Bioorganic & medicinal chemistry, 11-01, Volume: 24, Issue:21
Analysis of quinolinequinone reactivity, cytotoxicity, and anti-HIV-1 properties.
AID480962Antiproliferative activity against human T cells after 48 hrs by MTT assay2010Bioorganic & medicinal chemistry, May-01, Volume: 18, Issue:9
The anti-cancer, anti-inflammatory and tuberculostatic activities of a series of 6,7-substituted-5,8-quinolinequinones.
AID1631057Binding affinity to HIV1 MA expressed in bacterial expression system assessed as inhibition of protein binding to Sel15 RNA at 50 uM preincubated for 30 mins followed by Sel15 RNA addition measured after 30 mins in presence of beta-mercaptoethanol by elec2016Bioorganic & medicinal chemistry, 11-01, Volume: 24, Issue:21
Analysis of quinolinequinone reactivity, cytotoxicity, and anti-HIV-1 properties.
AID1631043Inhibition of HIV1 NL4-3 CA infected in human CEM T cells at 10 uM after 7 days by immunoblot analysis relative to control2016Bioorganic & medicinal chemistry, 11-01, Volume: 24, Issue:21
Analysis of quinolinequinone reactivity, cytotoxicity, and anti-HIV-1 properties.
AID1631049Inhibition of actin in human CEM T cells at 1 uM after 7 days by immunoblot analysis relative to control2016Bioorganic & medicinal chemistry, 11-01, Volume: 24, Issue:21
Analysis of quinolinequinone reactivity, cytotoxicity, and anti-HIV-1 properties.
AID1631060Binding affinity to HIV1 MA expressed in bacterial expression system assessed as inhibition of protein binding to Sel15 RNA at 50 uM preincubated for 30 mins followed by Sel15 RNA addition measured after 30 mins in presence of DTT by electrophoretic mobil2016Bioorganic & medicinal chemistry, 11-01, Volume: 24, Issue:21
Analysis of quinolinequinone reactivity, cytotoxicity, and anti-HIV-1 properties.
AID1597609Antiproliferative activity against human T47D cells assessed as reduction in cell viability incubated for 72 hrs by WST1 assay2019European journal of medicinal chemistry, Sep-01, Volume: 177Betulin-1,4-quinone hybrids: Synthesis, anticancer activity and molecular docking study with NQO1 enzyme.
AID1631050Cytotoxicity in HEK293T cells assessed as reduction in cell viability after 48 hrs by MTT assay2016Bioorganic & medicinal chemistry, 11-01, Volume: 24, Issue:21
Analysis of quinolinequinone reactivity, cytotoxicity, and anti-HIV-1 properties.
AID1631035Induction of CSILD IRQGP KEPFR DYVDR FYKTL RAEQA S peptide cross linking assessed as formation of dimer bands at 50 uM after 2 hrs by coomassie blue staining based electrophoresis2016Bioorganic & medicinal chemistry, 11-01, Volume: 24, Issue:21
Analysis of quinolinequinone reactivity, cytotoxicity, and anti-HIV-1 properties.
AID1434234Cytotoxicity against human SNB19 cells harboring undetectable levels of NQO1 after 72 hrs by WST1 assay2017European journal of medicinal chemistry, Jan-27, Volume: 126Alkynyloxy derivatives of 5,8-quinolinedione: Synthesis, in vitro cytotoxicity studies and computational molecular modeling with NAD(P)H:Quinone oxidoreductase 1.
AID1631047Inhibition of HIV1 NL4-3 p41 infected in human CEM T cells at 1 uM after 7 days by immunoblot analysis relative to control2016Bioorganic & medicinal chemistry, 11-01, Volume: 24, Issue:21
Analysis of quinolinequinone reactivity, cytotoxicity, and anti-HIV-1 properties.
AID1434239Selectivity index, ratio of IC50 for HFF1 to IC50 for human C32 cells harboring low levels of NQO12017European journal of medicinal chemistry, Jan-27, Volume: 126Alkynyloxy derivatives of 5,8-quinolinedione: Synthesis, in vitro cytotoxicity studies and computational molecular modeling with NAD(P)H:Quinone oxidoreductase 1.
AID1631056Binding affinity to HIV1 MA expressed in bacterial expression system assessed as inhibition of protein binding to Sel15 RNA at 50 uM preincubated for 30 mins followed by Sel15 RNA addition measured after 30 mins in presence of cysteine by electrophoretic 2016Bioorganic & medicinal chemistry, 11-01, Volume: 24, Issue:21
Analysis of quinolinequinone reactivity, cytotoxicity, and anti-HIV-1 properties.
AID1434236Cytotoxicity against human MCF7 cells harboring high levels of NQO1 after 72 hrs by WST1 assay2017European journal of medicinal chemistry, Jan-27, Volume: 126Alkynyloxy derivatives of 5,8-quinolinedione: Synthesis, in vitro cytotoxicity studies and computational molecular modeling with NAD(P)H:Quinone oxidoreductase 1.
AID1631040Induction of MLV PrGag cross linking transfected in HEK293T cells assessed as formation of protein dimer at 1mM after 1 hr by immunoblot analysis2016Bioorganic & medicinal chemistry, 11-01, Volume: 24, Issue:21
Analysis of quinolinequinone reactivity, cytotoxicity, and anti-HIV-1 properties.
AID1631033Inactivation of glutathione in sodium phosphate buffer at pH 7.4 assessed as GSH free sulfhydryl levels at 200 uM after 1 hr by spectrophotometric analysis2016Bioorganic & medicinal chemistry, 11-01, Volume: 24, Issue:21
Analysis of quinolinequinone reactivity, cytotoxicity, and anti-HIV-1 properties.
AID480963Antiinflammatory activity in human neutrophils assessed as inhibition of PMA-induced superoxide production after 20 mins by WST1 assay2010Bioorganic & medicinal chemistry, May-01, Volume: 18, Issue:9
The anti-cancer, anti-inflammatory and tuberculostatic activities of a series of 6,7-substituted-5,8-quinolinequinones.
AID1631034Induction of cysteine deficient 33 residue peptide cross linking assessed as formation of monomer/dimer bands by coomassie blue staining based electrophoresis2016Bioorganic & medicinal chemistry, 11-01, Volume: 24, Issue:21
Analysis of quinolinequinone reactivity, cytotoxicity, and anti-HIV-1 properties.
AID1631045Inhibition of actin in human CEM T cells at 10 uM after 7 days by immunoblot analysis relative to control2016Bioorganic & medicinal chemistry, 11-01, Volume: 24, Issue:21
Analysis of quinolinequinone reactivity, cytotoxicity, and anti-HIV-1 properties.
AID1631052Cytotoxicity in human CEM-SS cells assessed as reduction in cell viability after 48 hrs by MTT assay2016Bioorganic & medicinal chemistry, 11-01, Volume: 24, Issue:21
Analysis of quinolinequinone reactivity, cytotoxicity, and anti-HIV-1 properties.
AID1631042Inhibition of HIV1 NL4-3 PrGag infected in CEM T cells at 10 uM after 7 days by immunoblot analysis relative to control2016Bioorganic & medicinal chemistry, 11-01, Volume: 24, Issue:21
Analysis of quinolinequinone reactivity, cytotoxicity, and anti-HIV-1 properties.
AID1597606Antiproliferative activity against human COLO829 cells assessed as reduction in cell viability incubated for 72 hrs by WST1 assay2019European journal of medicinal chemistry, Sep-01, Volume: 177Betulin-1,4-quinone hybrids: Synthesis, anticancer activity and molecular docking study with NQO1 enzyme.
AID1597608Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by WST1 assay2019European journal of medicinal chemistry, Sep-01, Volume: 177Betulin-1,4-quinone hybrids: Synthesis, anticancer activity and molecular docking study with NQO1 enzyme.
AID1434242Selectivity index, ratio of IC50 for HFF1 to IC50 for human MCF7 cells harboring high levels of NQO12017European journal of medicinal chemistry, Jan-27, Volume: 126Alkynyloxy derivatives of 5,8-quinolinedione: Synthesis, in vitro cytotoxicity studies and computational molecular modeling with NAD(P)H:Quinone oxidoreductase 1.
AID157201Inhibitory Activity against Recombinant Human PTP12001Journal of medicinal chemistry, Nov-22, Volume: 44, Issue:24
Discovery and biological evaluation of a new family of potent inhibitors of the dual specificity protein phosphatase Cdc25.
AID1597607Antiproliferative activity against human C32 cells assessed as reduction in cell viability incubated for 72 hrs by WST1 assay2019European journal of medicinal chemistry, Sep-01, Volume: 177Betulin-1,4-quinone hybrids: Synthesis, anticancer activity and molecular docking study with NQO1 enzyme.
AID480964Antitubercular activity against Mycobacterium bovis BCG after 7 days by alamar blue assay2010Bioorganic & medicinal chemistry, May-01, Volume: 18, Issue:9
The anti-cancer, anti-inflammatory and tuberculostatic activities of a series of 6,7-substituted-5,8-quinolinequinones.
AID1631055Binding affinity to HIV1 MA expressed in bacterial expression system assessed as inhibition of protein binding to Sel15 RNA at 50 uM preincubated for 30 mins followed by Sel15 RNA addition measured after 30 mins in presence of glutathione by electrophoret2016Bioorganic & medicinal chemistry, 11-01, Volume: 24, Issue:21
Analysis of quinolinequinone reactivity, cytotoxicity, and anti-HIV-1 properties.
AID1434233Cytotoxicity against human C32 cells harboring low levels of NQO1 after 72 hrs by WST1 assay2017European journal of medicinal chemistry, Jan-27, Volume: 126Alkynyloxy derivatives of 5,8-quinolinedione: Synthesis, in vitro cytotoxicity studies and computational molecular modeling with NAD(P)H:Quinone oxidoreductase 1.
AID1597605Antiproliferative activity against human SNB19 cells assessed as reduction in cell viability incubated for 72 hrs by WST1 assay2019European journal of medicinal chemistry, Sep-01, Volume: 177Betulin-1,4-quinone hybrids: Synthesis, anticancer activity and molecular docking study with NQO1 enzyme.
AID1631054Antiviral activity against GFP-transducing HIV1 infected in HEK293T cells at 0.1 mM after 1 hr by GFP fluorescence assay2016Bioorganic & medicinal chemistry, 11-01, Volume: 24, Issue:21
Analysis of quinolinequinone reactivity, cytotoxicity, and anti-HIV-1 properties.
AID1631038Induction of GSH cross linking assessed as product formation at peak 792.3 m/z at 5 mM after 3 hrs by mass spectroscopic analysis2016Bioorganic & medicinal chemistry, 11-01, Volume: 24, Issue:21
Analysis of quinolinequinone reactivity, cytotoxicity, and anti-HIV-1 properties.
AID1631041Induction of MLV PrGag C>S mutant cross linking transfected in HEK293T cells assessed as formation of protein dimer at 1 mM after 1 hr by immunoblot analysis2016Bioorganic & medicinal chemistry, 11-01, Volume: 24, Issue:21
Analysis of quinolinequinone reactivity, cytotoxicity, and anti-HIV-1 properties.
AID1631048Inhibition of HIV1 NL4-3 CA infected in human CEM T cells at 1 uM after 7 days by immunoblot analysis relative to control2016Bioorganic & medicinal chemistry, 11-01, Volume: 24, Issue:21
Analysis of quinolinequinone reactivity, cytotoxicity, and anti-HIV-1 properties.
AID1393009Inhibition of human coxsackievirus B3 protease 3C expressed in Escherichia coli (BL21) using fluorogenic-Dabcyl-KEALFQGPPQFE-Edans as substrate after 1 hr by FRET assay2018Bioorganic & medicinal chemistry letters, 08-01, Volume: 28, Issue:14
Identification of quinone analogues as potential inhibitors of picornavirus 3C protease in vitro.
AID1631037Induction of GSH cross linking assessed as product formation at peak 770.3 m/z at 5 mM after 3 hrs by mass spectroscopic analysis2016Bioorganic & medicinal chemistry, 11-01, Volume: 24, Issue:21
Analysis of quinolinequinone reactivity, cytotoxicity, and anti-HIV-1 properties.
AID51883Inhibitory activity against recombinant human cell division cycle 25B2001Journal of medicinal chemistry, Nov-22, Volume: 44, Issue:24
Discovery and biological evaluation of a new family of potent inhibitors of the dual specificity protein phosphatase Cdc25.
AID1434237Cytotoxicity against HFF1 after 72 hrs by WST1 assay2017European journal of medicinal chemistry, Jan-27, Volume: 126Alkynyloxy derivatives of 5,8-quinolinedione: Synthesis, in vitro cytotoxicity studies and computational molecular modeling with NAD(P)H:Quinone oxidoreductase 1.
AID1434241Selectivity index, ratio of IC50 for HFF1 to IC50 for human MDA-MB-231 cells harboring undetectable levels of NQO12017European journal of medicinal chemistry, Jan-27, Volume: 126Alkynyloxy derivatives of 5,8-quinolinedione: Synthesis, in vitro cytotoxicity studies and computational molecular modeling with NAD(P)H:Quinone oxidoreductase 1.
AID1434235Cytotoxicity against human MDA-MB-231 cells harboring undetectable levels of NQO1 after 72 hrs by WST1 assay2017European journal of medicinal chemistry, Jan-27, Volume: 126Alkynyloxy derivatives of 5,8-quinolinedione: Synthesis, in vitro cytotoxicity studies and computational molecular modeling with NAD(P)H:Quinone oxidoreductase 1.
AID1631059Antiviral activity against HIV1 infected in HEK293T cells at 0.1 to 1 mM after 1 hr by luciferase reporter gene assay relative to control2016Bioorganic & medicinal chemistry, 11-01, Volume: 24, Issue:21
Analysis of quinolinequinone reactivity, cytotoxicity, and anti-HIV-1 properties.
AID1597610Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 72 hrs by WST1 assay2019European journal of medicinal chemistry, Sep-01, Volume: 177Betulin-1,4-quinone hybrids: Synthesis, anticancer activity and molecular docking study with NQO1 enzyme.
AID1631044Inhibition of HIV1 NL4-3 p41 infected in human CEM T cells at 10 uM after 7 days by immunoblot analysis relative to control2016Bioorganic & medicinal chemistry, 11-01, Volume: 24, Issue:21
Analysis of quinolinequinone reactivity, cytotoxicity, and anti-HIV-1 properties.
AID217196Inhibitory Activity against Recombinant Human VHR2001Journal of medicinal chemistry, Nov-22, Volume: 44, Issue:24
Discovery and biological evaluation of a new family of potent inhibitors of the dual specificity protein phosphatase Cdc25.
AID1597611Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 72 hrs by WST1 assay2019European journal of medicinal chemistry, Sep-01, Volume: 177Betulin-1,4-quinone hybrids: Synthesis, anticancer activity and molecular docking study with NQO1 enzyme.
AID1631036Induction of HIV1 MA cross linking assessed as formation of protein dimer at 50 uM after 2 hrs by immunoblot analysis2016Bioorganic & medicinal chemistry, 11-01, Volume: 24, Issue:21
Analysis of quinolinequinone reactivity, cytotoxicity, and anti-HIV-1 properties.
AID1631039Induction of immature HIV1 PrGag cross linking transfected in HEK293T cells assessed as formation of protein dimer at 1 mM after 1 hr by immunoblot analysis2016Bioorganic & medicinal chemistry, 11-01, Volume: 24, Issue:21
Analysis of quinolinequinone reactivity, cytotoxicity, and anti-HIV-1 properties.
AID1631051Cytotoxicity in human MT4 cells assessed as reduction in cell viability after 48 hrs by MTT assay2016Bioorganic & medicinal chemistry, 11-01, Volume: 24, Issue:21
Analysis of quinolinequinone reactivity, cytotoxicity, and anti-HIV-1 properties.
AID1631032Binding affinity to HIV1 MA expressed in bacterial expression system assessed as inhibition of protein binding to Sel15 RNA at 100 uM preincubated for 30 mins followed by Sel15 RNA addition measured after 30 mins by electrophoretic mobility shift assay2016Bioorganic & medicinal chemistry, 11-01, Volume: 24, Issue:21
Analysis of quinolinequinone reactivity, cytotoxicity, and anti-HIV-1 properties.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (10)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (10.00)18.7374
1990's0 (0.00)18.2507
2000's3 (30.00)29.6817
2010's6 (60.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.00

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.00 (24.57)
Research Supply Index2.40 (2.92)
Research Growth Index4.40 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.00)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other10 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
isoniazid
Hydra: A genus of freshwater polyps in the family Hydridae, order Hydroida, class HYDROZOA. They are of special interest because of their complex organization and because their adult organization corresponds roughly to the gastrula of higher animals.. hydrazide : Compounds derived from oxoacids RkE(=O)l(OH)m (l =/= 0) by replacing -OH by -NRNR2 (R groups are commonly H). (IUPAC).		6.9710carbohydrazideantitubercular agent;
drug allergen
6-anilino-5,8-quinolinedione
6-anilino-5,8-quinolinedione: structure given in first source; SRS-A & guanylate cyclase antagonist. 6-anilino-5,8-quinolinedione : A quinolone that is quinoline-5,8-dione in which the hydrogen at position 6 is replaced by an anilino group.		2.1310aminoquinoline;
aromatic amine;
p-quinones;
quinolone		antineoplastic agent;
EC 4.6.1.2 (guanylate cyclase) inhibitor
dichlone
dichlone: structure		2.8730
podophyllotoxin
Podophyllum: A genus of poisonous American herbs, family BERBERIDACEAE. The roots yield PODOPHYLLOTOXIN and other pharmacologically important agents. The plant was formerly used as a cholagogue and cathartic. It is different from the European mandrake, MANDRAGORA.		2.2110furonaphthodioxole;
lignan;
organic heterotetracyclic compound		antimitotic;
antineoplastic agent;
keratolytic drug;
microtubule-destabilising agent;
plant metabolite;
tubulin modulator
1,6-bismaleimidohexane
[no description available]		2.1310
2,2'-dipyridyl disulfide
2,2'-dipyridyl disulfide: disulfide is an important moiety in this cpd. aldrithiol : A member of the class of pyridines that is pyridine which is substituted by a pyridin-2-yldisulfanediyl group at position 2. It is a reagent used in molecular biology as an oxidizing agent. Also used in peptide synthesis and for detecting thiols.		2.1310organic disulfide;
pyridines		oxidising agent
lissamine rhodamine b
lissamine rhodamine B: RN given refers to parent cpd; Lissamine Rhodamine B refers to Na salt		2.0210
betulin
betulin: isolated from various white birch bark (BETULA). betulin : A pentacyclic triterpenoid that is lupane having a double bond at position 20(29) as well as 3beta-hydroxy and 28-hydroxymethyl substituents.		2.2110diol;
pentacyclic triterpenoid		analgesic;
anti-inflammatory agent;
antineoplastic agent;
antiviral agent;
metabolite
6-amino-7-chloro-5,8-dioxoquinoline
6-amino-7-chloro-5,8-dioxoquinoline: quinone structure important in this cpd; structure		2.4920
nsc 663284
NSC 663284: structure in first source		2.4520quinolone
nsc668394
[no description available]		210
y 27632
Y 27632: RN given for di-HCl salt; inhibits Rho-associated protein kinase; inhibits calcium sensitization to affect smooth muscle relaxation; structure in first source. Y-27632 : A monocarboxylic acid amide that is trans-[(1R)-1-aminoethyl]cyclohexanecarboxamide in which one of the nitrogens of the aminocarbony group is substituted by a pyridine nucleus. It has been shown to exhibit inhibitory activity against Rho-associated protein kinase (ROCK) enzyme.		2.2110aromatic amide
stilbenes
Stilbenes: Organic compounds that contain 1,2-diphenylethylene as a functional group.. trans-stilbene : The trans-isomer of stilbene.		2.2110stilbene
naphthoquinones
Naphthoquinones: Naphthalene rings which contain two ketone moieties in any position. They can be substituted in any position except at the ketone groups.		2.2110
fosbretabulin
fosbretabulin: a microtubule destabilizing agent isolated from Combretum caffrum; structure in first source		2.2110
ConditionIndicatedRelationship StrengthStudiesTrials
Benign Neoplasms
[description not available]		02.2110
Neoplasms
New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.		02.2110